CSF3 and stroke disorder: Evidence from 14 studies that met the inclusion criteria for this meta-analysis indicated that G-CSF treatment in a cumulative dosage range from1–135 μg/kg/day did not produce significant SAEs in stroke patients; however, the small numbers of participants included in each trial made it difficult to make definitive conclusions about the safety of G-CSF therapy in stroke patients, especially considering the observed effect on leukocyte count.